Kornimate/medical-research-clean huggingface dataset:
prevalence and progression of periodontitis in ankylosing spondylitis

Conditions: Ankylosing Spondylitis; Periodontitis

Summary: 1. our hypotheses on the relationship between periodontitis and as are as follows; * the prevalence of periodontitis is higher in as patients group than that of non-as control group * anti-tnf-α therapy would favorably affect the disease course of periodontitis. 2. based on our hypotheses, the specific objectives of the present proposal are as follows; * the primary objective is to compare the prevalence rate of periodontitis between as patient group and non-as group. * the secondary objectives will be: * to observe the carriage rate of p. gingivalis in as and non-as groups * to identify clinical parameters associated with the severity of periodontitis in as group. * to compare the progression of periodontitis at weeks 12 and 24 between as and non-as groups or between as patients with and without anti-tnf-α treatment


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * subjects giving informed written consent * in case of as patients, subjects to meet the 1984 modified new york criteria for as. * in case of controls, subjects without a history of inflammatory arthropathy exclusion criteria: * subjects having received periodontitis treatment including scaling within 6 months before study participation. * subjects with a history of taking antibiotics including prophylactic anti-tuberculosis agents within 3 months before study participation. * subjects with a hitory of taking immuno-suppresives (methotrexate, leflunomide, tacrolimus, cyclosporin, or azathioprine) or any dose of glucocorticoids (oral or pareneral) within 3 months before study participation. * subjects with a history of diabetes mellitus. * subjects with aggressive periodontitis requiring open flap debriment at enrollment immediately. * subjects with a hitory of clinical inflammatory bowel disease. * subjects with active infection, which can make an influence on the levels of acute phase reactants. * subjects with any other condition to render the patient unable to understand the scope of the study or preclude the patient from following the protocol in the physician's opinion.
emergency management in a dedicated respiratory unit of patients with a possible covid-19 infection

Conditions: Emergencies

Summary: this research aims to improve knowledge of the epidemiology of patients consulting in the covid possible respiratory units (recop unit). indeed, the epidemic linked to covid19 affects france and impacts its health system. the reception of all intermediate patients will be on the emergency structures (su). indeed, the french healthcare system centralizes unscheduled urgent care on the er. the aspecific respiratory symptomatology in "intermediate" patients indicates them all the more at an admission to su or the diagnostic approach to respiratory difficulty may be carried out. it will be necessary to identify the diagnosis of the dyspneic patient and to define his virological status covid before referring him to the appropriate units. the investigatory propose an original strategy of dedicating entire care sectors to the care of patients admitted for dyspnea in our er. these units will be named recop units. this study would improve epidemiological knowledge of covid-19 and ability to receive these patients within the su.


Eligibility criteria:
inclusion criteria: * all patients over the age of 15 admitted to the recop unit for dyspnea exclusion criteria: * patient admitted to shock for respiratory distress requiring immediate respiratory support. * patient under justice safeguard

Keywords: covid 19 aspecific respiratory symptomatology
treatment of intermittent claudication by g-csf-mobilized pb-mnc

Conditions: Intermittent Claudication; PAD; Atherosclerotic Ischemic Disease

Summary: this study will investigate the efficacy of g-csf mobilized mononuclear cell injection of patients with pad who presented with intermittent claudication. forty pad patients who presented with intermittent claudication will be randomized into 2 groups. the control group will be treated by medication and walking exercise 3 times/ week. the experiment group will be injected g-csf mobilized mononuclear cell ,medication and walking exercise 3 times/ week. ankle brachial index(abi), toe brachial index (tbi) and transcutaneous oxygen measurement will be evaluated at the day of randomization, 1 , 3, 6 and 12 months

this study will investigate the efficacy of g-csf mobilized mononuclear cell injection of patients with pad who presented with intermittent claudication. forty pad patients who presented with intermittent claudication will be randomized into 2 groups. the control group will be treated by medication and walking exercise 3 times/ week. the experiment group will be injected g-csf mobilized mononuclear cell ,medication and walking exercise 3 times/ week. ankle brachial index(abi), toe brachial index (tbi) and transcutaneous oxygen measurement will be evaluated at the day of randomization, 1 , 3, 6 and 12 months in the control group and day of randomization, 1 , 3, 6 and 12 months after injection of pb-mnc in the experiment group. pain free walking distance will be evaluated at the day of randomization, 1 , 3, 6 and 12 months by pedometer.

Eligibility criteria:
inclusion criteria: * patients with chronic arterial occlusive disease who presented with intermittent claudication exclusion criteria: * recent myocardial infarction * severe valvular heart disease * after organ transplantation * cardiomyopthy( ef\< 25%) * liver failure * coagulopathy * hiv * pregnancy
trial of nanopac focal therapy for prostate cancer

Conditions: Prostate Cancer; Prostate Adenocarcinoma; Prostate Cancer Adenocarcinoma; Prostatic Neoplasm; Urogenital Neoplasms; Genital Neoplasms, Male; Localized Cancer

Summary: this study evaluates the use of nanopac injected directly into the prostate lesion in men with prostate cancer.

nanopac is very small (submicron) particles of the chemotherapy drug, paclitaxel, which is administered intravenously in a number of types of cancer. these submicron particles are injected directly into solid tumors to target cancer at the site of disease with less systemic exposure than intravenously administered chemotherapy. in this study, this submicron particle paclitaxel will be injected directly into the prostate lesion in men with prostate cancer scheduled for prostatectomy on up to three different occasions. all subjects in the study will receive nanopac and will be evaluated to see if nanopac is safe, well-tolerated, and has an impact on prostate cancer.

Eligibility criteria:
inclusion criteria: * at least 18 years of age; * histopathologically proven adenocarcinoma of the prostate: * localized cancer; * subjects with tumors classified as \<t3 per tnm classification, gleason score≥ 6; * prostate tumor must be able to be visualized on mpmri; * already considered to be candidate for radical prostatectomy; * considered appropriate for treatment with paclitaxel therapy; * laboratory requirements: * wbc \>2500/mm3 * neutrophil \>1500/mm3 * hemoglobin \>10 mg/dl * platelet \>100,000/ mm3 * ast and alt \<2.5 x uln * total bilirubin \<1.5 x uln * calculated creatinine clearance ≥ 30 ml/min * normal pt/inr and ptt; * ecog of 0 or 1; * international prostate symptom score (i-pss) less than or equal to 20; * if sexually active, willing to use double condoms from time of nanopac injection until prostatectomy; * agree to all study procedures and provide signed informed consent; exclusion criteria: * evidence of locally advanced or metastatic disease; * prostate size ≥ 50 cc; * prior prostatectomy, including surgery for any benign condition (such as turp); * anticipated use of concomitant chemotherapy (other than the protocol specified agents), immunotherapy, or systemic use of hormonal therapy (such as gnrh analogs, antiandrogens, androgen receptor inhibitors, and 5-α reductase inhibitors) while on study prior to surgery; * treatment with a prior investigational medication within 30 days of first dose of study agent; * any previous local treatment of the prostate (e.g. radiation, hifu, cryotherapy, focal irreversible electroporation, photodynamic therapy, laser induced thermometry); * any other condition (e.g., psychiatric disorder) that, in the opinion of the investigator, may interfere with the subject's ability to comply with the study requirements or visit schedule; * known sensitivity to any of the study agent components; * history of prior malignancy that has not been in remission for \>5 years, with the exception of basal cell or squamous cell carcinoma.

Keywords: paclitaxel
ketamine in severe traumatic brain injury

Conditions: Traumatic Brain Injury; Traumatic Encephalopathy

Summary: traumatic brain injury (tbi) accounts for approximately 2.5 million visits to emergency departments in the united states each year. after decades of research, management strategies for severe tbi (stbi) patients are still evolving. optimizing intracranial pressure (icp) and cerebral perfusion pressure (cpp) are paramount in the management of these patients and placement of these monitors is the current standard-of-care. however, monitoring brain oxygenation (pbto2) with invasive intraparenchymal monitors is currently under investigation in the management of severe tbi and placement of these monitors is gaining widespread use. this has opened the door for the use of tiered therapy to optimize icp and pbto2 simultaneously. current evidence indicates that correction of icp, cpp and pbto2 in stbi requires optimized analgesia and sedation. ketamine is one of the few drugs available that has both sedative and analgesic properties and does not commonly compromise respiratory drive like opioids and sedative-hypnotics. however, traditionally, ketamine has been viewed as contraindicated in the setting of tbi due to concerns for elevation in icp. yet, new data has cast this long-held assumption into significant doubt. hence the present pilot study will characterize the neurophysiological response to a single dose of ketamine in critically-ill tbi patient with icp and pbto2 monitoring.


Eligibility criteria:
inclusion criteria: * severe traumatic brain injury * placement of intracranial monitor for measurement of intracranial pressure and brain tissue oxygenation * age greater than or equal to 18 years exclusion criteria: * documented allergy to ketamine * sinus tachycardia with sustained heart rate \>120 * any episode of non-sinus tachycardia * documented history of schizophrenia * systolic blood pressure \> 180, diastolic blood pressure \> 120 * documented episode(s) of icp elevations \>25 mm hg sustained greater than 5 minutes within 24 hours * similar episodes as above of pbto2 \<15 mmhg * positive pregnancy test and/or is currently breast-feeding

Keywords: ketamine traumatic brain injury
afatinib (bibw2992) in her2 (human epidermal growth factor receptor 2)-overexpressing inflammatory breast cancer

Conditions: Breast Neoplasms

Summary: the general aim of this study is to investigate the efficacy and safety of afatinib alone and in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy within this trial) as treatment in patients with her2-overexpressing, locally advanced or metastatic inflammatory breast cancer. the study will include patients who have and have not failed prior trastuzumab treatment.


Eligibility criteria:
inclusion criteria: 1. female patients \>=18 years with proven diagnosis of her2-overexpressing, histologically confirmed breast cancer 2. locally advanced or metastatic disease 3. must have disease that can be evaluated according to recist 1.1 (response evaluation criteria for solid tumours version 1.1) 4. for trastuzumab pre-treated patients, must have failed prior trastuzumab treatment 5. investigator-confirmed diagnosis of inflammatory breast cancer 6. must have biopsiable disease exclusion criteria: 1. prior treatment with her2-targeted small molecules or antibodies other than trastuzumab (which must have been given in the trastuzumab-failure study population) 2. must not have received prior vinorelbine treatment
assessment of serum cd25 level in systemic sclerosis patients with or without interstitial lung disease (ild)

Conditions: Assessment of Serum Level of SCD25 in RA, SSc (with or Without ILD) and IPF and Its Correlation with Disease Activity

Summary: assessment of serum level of scd25 in ssc (with or without ild) and its correlation with disease activity. evaluating the clinical correlation of serum soluble cd25 (scd25) in systemic sclerosis (ssc) (with or without ild).

interstitial lung disease (ild) comprises of a large group of idiopathic diffuse processes that affect the lung parenchyma. connective tissue disease-associated lung disease (ctd-ild) represents one of the most common causes of ild. along with idiopathic pulmonary fibrosis (ipf), they both represent the majority of ilds. since ctd-ild typically follows a better clinical course compared to ipf, and hence therapies differ substantially between them, an accurate diagnosis is critical. up to 30% of newly diagnosed ild will be due to ctd. this underscores the importance of investigating all patients with ild for possible underlying ctd. systemic sclerosis (ssc) is a systemic autoimmune disease in which inflammation and fibrosis play a crucial role and lead to severe damage and failure of multiple organs such as the skin, joints, tendons, gastrointestinal tract, lungs, heart, blood vessels, and kidneys. in ssc, the presence of ild is even more common (≥80%); in addition, pulmonary hypertension (ph), also in the absence of diffuse lung disease, can be demonstrated by cardiac catheterisation in 10% of cases. these conditions are the two main prognostic factors for ssc patients; in fact 40% of deaths in ssc are attributable to pulmonary pathology (4). cd25, the il-2 receptor α chain, is one subunit of the high-affinity il-2 receptor (il2r), which is comprised of il2r alpha (cd25), beta (cd122), and the common gamma chain (cd132). it is well known that soluble cd25 (scd25) is generated as a consequence of proteolytic cleavage, mainly from the membrane of activated t cells, and the serum concentrations of scd25 are associated with the proliferation of activated t cells. high serum scd25 levels have been reported in patients with various autoimmune diseases. previous studies have shown that scd25 can act as an early inhibitor of t-cell response related to il-2 signalling. in the experimental autoimmune encephalomyelitis (eae) model, scd25 can enhance the th17 response and exacerbate eae by prohibiting signalling by sequestering the local il-2 and il-2r interaction. scd25 can efficiently bind to secreted il-2, suggesting its ability to serve as a decoy receptor for il-2 to play a pathogenic role in autoimmunity development.

Eligibility criteria:
1. inclusion criteria: ssc patients fulfilled the 2013 acr/eu lar criteria (10). adult age above 18 years. 2. exclusion criteria: * patients unwilling to participate in the study. * patients with other autoimmune diseases. * patients with interstitial lung disease (ild) caused by causes other than systemic sclerosis.
the use of intermittent pneumatic compression device for symptomatic relief in patients with post thrombotic syndrome

Conditions: Post Thrombotic Syndrome

Summary: the use of activecare+s.f.t 3rd generation (an intermittent pneumatic compression device) will improve quality of life in patients suffering from post thrombotic syndrome compared to compression stockings which is the current gold standard of care.


Eligibility criteria:
inclusion criteria: * patients who have developed post thrombotic leg symptoms after a deep vein thrombosis event. exclusion criteria: * admitted patients * patients who suffer from peripheral artery disease. * patients with an acute deep vein thrombosis. * s/p leg skin transplant * patients with an active leg infection * patients who aren't capable of operating the device.
the efect of azithromicyn on bronchopulmonary displasia in extremely preterm and very preterm infant

Conditions: Bronchopulmonary Dysplasia; Intraventricular Hemorrhage; Necrotizing Enterocolitis

Summary: this study was to see the effectiveness of azithromycin in preventing the incidence of bronchopulmonary dysphasia in extremely preterm and very premature infants. inclusion criteria were infants with a gestational age of 25-31 weeks 6 days who experienced respiratory distress and their families had agreed to participate in the study, then randomized. the intervention was in the form of giving azithromycin in the intervention group and no intervention was carried out in the control group and then followed up to 36 weeks pma


Eligibility criteria:
inclusion criteria: * premature infant 25-31 weeks 6 days with respiratory distress, exclusion criteria: * multiple congenital anomaly
therapeutic endpoint in pediatric ibd conditions

Conditions: Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease

Summary: the purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (ibd), specifically subtypes crohn's disease (cd) and ulcerative colitis (uc). the novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. data from the device provides an assessment of disease activity and a more precise approach to treatment.


Eligibility criteria:
inclusion criteria: * male or female ≥ 6 years of age at screening. * documentation of an ibd diagnosis as evidenced by history exclusion criteria: * documented history of eye disease precluding pupillometry * patients who are unwilling or unable to participate due to developmental delays or ongoing psychological diagnoses.
heart rate variability and hyperthyroidism: evaluation of the short-term effects of propanolol

Conditions: Hyperthyroidism

Summary: objective: the aim of our study was to evaluate the short term effects of propanolol on heart rate variability in patients with hyperthyroidism. design: in ten patients newly diagnosed as having hyperthyroidism and naïve of all treatment specific for hyperthyroidism, we evaluated the short term effects of propanolol on heart rate variability (hrv). methods: we measured heart rate variability by power spectral analysis during 2 hours of rest and during ewing's tests before and after the administration of propanolol 40mg/12 hours orally for 72 hours.

objective: the aim of our study was to evaluate the short term effects of propanolol on heart rate variability in patients with hyperthyroidism. design: in ten patients newly diagnosed as having hyperthyroidism and naïve of all treatment specific for hyperthyroidism, we evaluated the short term effects of propanolol on heart rate variability (hrv). methods: we measured heart rate variability by power spectral analysis during 2 hours of rest and during ewing's tests before and after the administration of propanolol 40mg/12 hours orally for 72 hours. other outcomes included mean heart rate, mean r-r interval during 2-hour rest. the study questions the systematic adjunction of propanolol early in the treatment of hyperthyroidism.

Eligibility criteria:
inclusion criteria: * consenting patients referred to or diagnosed at the national centre of obesity of the yaounde central hospital as having hyperthyroidism * naïve of all treatment specific for hyperthyroidism. * aged 18-70 years exclusion criteria: * patients already under a specific treatment for hyperthyroidism * patients taking beta blockers or any other cardiospecific treatment * patients presenting complications including acute thyrotoxic crisis, or symptomatic cardiac failure * contraindications to the prescription of beta blockers

Keywords: hyperthyroidism heart rate variability propanolol africa
the relationship between the neural drive and intrinsic positive end-expiratory pressure

Conditions: Chronic Obstructive Pulmonary Disease

Summary: to investigate the relation the nreural drive and intrinsic positive end-expiratory pressure(peepi) of the chronic obstructive pulmonary disease(copd) patients with respiratory failure.in present study the peepi of copd patients was increased by increasing the resistance of the respiratory system, the change of the neural drive was recorded.

to investigate the relation the nreural drive and intrinsic positive end-expiratory pressure(peepi) of the chronic obstructive pulmonary disease(copd) patients with respiratory failure.the diaphragm electromyogram (emgdi) represents the neural drive to the diaphragm.a multi-pair esophageal electrode catheter was used to record the emgdi.the peepi was assessed by the by the balloon-catheter in the multi-pair esophageal electrode catheter. in present study the peepi of copd patients was increased by increasing the resistance of the respiratory system, the change of the neural drive( emgdi) was obtained from the a multi-pair esophageal electrode catheter all the signal recorded in the computer. the relation the nreural drive assessed by emgdi and intrinsic positive end-expiratory pressure(peepi) would be analysed.

Eligibility criteria:
inclusion criteria: chronic obstructive pulmonary disease patients with respiratory failure exclusion criteria: 1. heart failure 2. cardiac dysrhythmia 3. loss of consciousness

Keywords: neural respiratory drive intrinsic positive end-expiratory pressure chronic obstructive pulmonary disease patients